CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
Ourania Tatsis, SVP, Cro, sold 632 shares in Vertex Pharmaceuticals (VRTX) for $106,247 on Oct 01, 2019. Tatsis, after the transactions delineated in the...
Vertex Pharmaceuticals (VRTX) said it has entered into a five-year agreement with Scottish authorities to supply drugs used to treat cystic fibrosis. The...
Vertex Pharmaceuticals' (VRTX) average rating among analysts is a buy, with an average price target of $210. Price: 181.50, Change: +1.48, Percent Change:...
| Address | 50 Northern Avenue Boston, Massachusetts 02210 |
| Phone | +1.617.341.6100 |
| Number of Employees | 2,500 |
| Recent SEC Filing | 10/04/2019 4 |
| Chairman, President & Chief Executive Officer | Jeffrey M. Leiden |
| Chief Financial Officer & Executive Vice President | Charles F. Wagner |
| Chief Scientific Officer & EVP-Global Research | David Matthew Altshuler |
| Chief Medical Officer & Executive Vice President | Reshma Kewalramani |
| Price Open | $171.44 |
| Previous Close | $170.22 |
| 52 Week Range | $151.80 - 195.81 |
| Market Capitalization | $44.3 B |
| Shares Outstanding | 257.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/23/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 20.21 |
| Earnings per Share | $8.44 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.0 B |
| Net Profit Margin | 64.55% |
| Return on Equity | 51.71% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
